Literature DB >> 2176268

Gastroenteritis in suckling mice caused by human rotavirus can be prevented with egg yolk immunoglobulin (IgY) and treated with a protein-bound polysaccharide preparation (PSK).

T Ebina1, K Tsukada, K Umezu, M Nose, K Tsuda, H Hatta, M Kim, T Yamamoto.   

Abstract

Oral inoculation of human rotavirus MO strain (serotype 3) into 5-day-old BALB/c mice cause gastroenteritis characterized by diarrhea. Clinical symptoms, histopathological changes in the small intestine, and the detection of rotavirus antigen in enterocytes were all characteristic of rotavirus-induced gastroenteritis. Using this small animal model, passive protection of suckling mice against human rotavirus infection was achieved with the use of immunoglobulin (IgY) from the yolks of eggs of rotavirus-immunized hens. When IgY against a rotavirus strain homotypic to the challenge virus (MO strain) was administered in the mice, complete protection against rotavirus infection was achieved. On the other hand, with oral administration of IgY against a heterotypic strain (serotype 1, Wa strain), a lower protective effect was nevertheless obtained. The four different strains of human rotavirus (Wa, KUN, MO, and ST3) were inactivated in vitro by treatment with PSK, a protein-bound polysaccharide preparation, in a dose-dependent manner. Oral administration of 2.5 mg of PSK caused a therapeutic effect on experimentally MO-infected suckling mice. The antiviral effect of PSK was indicated by the reduction of the duration of diarrhea.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2176268     DOI: 10.1111/j.1348-0421.1990.tb01037.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  9 in total

Review 1.  Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections.

Authors:  D Carlander; H Kollberg; P E Wejåker; A Larsson
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Protective efficacy of a sulfated sialyl lipid (NMSO3) against human rotavirus-induced diarrhea in a mouse model.

Authors:  Kazuo Takahashi; Kazutaka Ohashi; Yurika Abe; Shuichi Mori; Koki Taniguchi; Takusaburo Ebina; Osamu Nakagomi; Masaki Terada; Shiro Shigeta
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Passive protection against bovine rotavirus in calves by specific immunoglobulins from chicken egg yolk.

Authors:  M Kuroki; M Ohta; Y Ikemori; R C Peralta; H Yokoyama; Y Kodama
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Development of Genotype-Specific Anti-Bovine Rotavirus A Immunoglobulin Yolk Based on a Current Molecular Epidemiological Analysis of Bovine Rotaviruses A Collected in Japan during 2017-2020.

Authors:  Koki Odagiri; Nobuki Yoshizawa; Hisae Sakihara; Koji Umeda; Shofiqur Rahman; Sa Van Nguyen; Tohru Suzuki
Journal:  Viruses       Date:  2020-12-03       Impact factor: 5.048

5.  Experimental Methods to Study the Pathogenesis of Human Enteric RNA Viruses.

Authors:  Somya Aggarwal; Ebrahim Hassan; Megan T Baldridge
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

6.  Successful treatment of rotavirus-induced diarrhoea in suckling mice with egg yolk immunoglobulin.

Authors:  Shafiqul A Sarker; Neha Pant; Lekh R Juneja; Lennart Hammarström
Journal:  J Health Popul Nutr       Date:  2007-12       Impact factor: 2.000

7.  I, 5. Treatment of viral gastroenteritis.

Authors:  Dorsey Bass
Journal:  Perspect Med Virol       Date:  2004-09-14

8.  Multiple-dose therapy with bovine colostrum confers significant protection against diarrhea in a mouse model of human rotavirus-induced gastrointestinal disease.

Authors:  M Inagaki; M Yamamoto; T Yabe; K Uchida; M Kawasaki; T Nakagomi; O Nakagomi; N Minamoto; Y Kanamaru
Journal:  J Dairy Sci       Date:  2012-11-29       Impact factor: 4.034

Review 9.  Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.

Authors:  Lucia Lee; Kate Samardzic; Michael Wallach; Lyn R Frumkin; Daria Mochly-Rosen
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.